Article: Bristol-Myers Squibb and Otsuka Pharmaceutical Company Launch New Rapidly Disintegrating Oral Antipsychotic Medication ABILIFY(R) DISCMELT(TM) (aripiprazole).

Provides Another ABILIFY Formulation Option for Adults With Schizophrenia or Manic Episodes of Bipolar I Disorder

PRINCETON, N.J. and TOKYO, Aug. 17 /PRNewswire-FirstCall/ -- Bristol-Myers Squibb Company and Otsuka Pharmaceutical Co., Ltd. today announced the launch of ABILIFY(R) DISCMELT(TM) (aripiprazole) Orally Disintegrating Tablets, a new oral form of the antipsychotic medication ABILIFY(R) (aripiprazole) that disintegrates rapidly in the mouth. The U.S. Food and Drug Administration (FDA) approved ABILIFY DISCMELT on June 7, 2006.

ABILIFY DISCMELT provides a convenient alternative for adults with schizophrenia or manic episodes associated with ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!